摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide | 1187089-84-4

中文名称
——
中文别名
——
英文名称
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide
英文别名
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)thiazol-4-carboxamide;N-[4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide化学式
CAS
1187089-84-4
化学式
C21H21F2N5OS
mdl
——
分子量
429.493
InChiKey
XTWKGZGHOUXMKG-OLZOCXBDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    112
  • 氢给体数:
    2
  • 氢受体数:
    8

文献信息

  • [EN] PIM KINASE INHIBITORS AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE PIM KINASE ET LEURS PROCÉDÉS D'UTILISATION
    申请人:NOVARTIS AG
    公开号:WO2009109576A1
    公开(公告)日:2009-09-11
    The present invention relates to new compounds of Formulas (I) and (II), their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pirn kinase activity and/or the prophylaxis or treatment of cancer.
    本发明涉及公式(I)和(II)的新化合物,它们的互变异构体、立体异构体和多型体,以及其药学上可接受的盐、酯、代谢物或前药,新化合物与药学上可接受的载体的组合物,以及新化合物的用途,单独或与至少一种额外治疗剂联合使用,用于抑制Pirn激酶活性和/或预防或治疗癌症。
  • Pim kinase inhibitors and methods of their use
    申请人:Burger Matthew
    公开号:US20100216839A1
    公开(公告)日:2010-08-26
    The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
    本发明涉及公式I和II的新化合物,它们的互变异构体、立体异构体和多晶形态,以及其药学上可接受的盐、酯、代谢物或前药,新化合物与药学上可接受的载体的组合物,以及新化合物的用途,单独或与至少一种额外治疗剂联合使用,在抑制Pim激酶活性和/或预防或治疗癌症方面。
  • PIM KINASE INHIBITORS AND METHODS OF THEIR USE
    申请人:Burger Matthew
    公开号:US20120202851A1
    公开(公告)日:2012-08-09
    The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
    本发明涉及公式I和II的新化合物,它们的互变异构体、立体异构体和多晶形式,以及其药学上可接受的盐、酯、代谢产物或前药,新化合物与药学上可接受的载体的组成物,以及新化合物的用途,单独或与至少一种额外的治疗剂联合使用,用于抑制Pim激酶活性和/或预防或治疗癌症。
  • PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers
    申请人:UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    公开号:US10842785B2
    公开(公告)日:2020-11-24
    The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.
    本发明提供了一种治疗癌症和/或减少癌细胞增殖的方法,该方法包括向需要这种治疗的受试者施用一种组合物,该组合物包含一种PIM激酶抑制剂,该PIM激酶抑制剂与一种调节/抑制RNA剪接因子蛋白活性的化合物相结合,可显示出mRNA剪接的变化。此外,mRNA 的剪接变化和 RNA 剪接因子的磷酸化可用作患者对抗 PIM 治疗反应性的生物标志物,还可提示有效的组合疗法,包括协同组合疗法。
  • PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers
    申请人:UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    公开号:US11389440B2
    公开(公告)日:2022-07-19
    The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes in expressed RNA or ribosomal binding proteins in combination with a compound that inhibits autophagy.
    本发明提供了一种治疗癌症和/或减少癌细胞增殖的方法,该方法包括向需要这种治疗的受试者施用一种组合物,该组合物包含一种 PIM 激酶抑制剂,该抑制剂与一种抑制自噬的化合物结合使用,后者在表达的 RNA 或核糖体结合蛋白中显示出变化。
查看更多